Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

SABS

SAB Biotherapeutics (SABS)

SAB Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SABS
DateTimeSourceHeadlineSymbolCompany
03/16/20234:28PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SABSSAB Biotherapeutics Inc
03/02/20239:18AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SABSSAB Biotherapeutics Inc
02/13/20236:08AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SABSSAB Biotherapeutics Inc
02/09/20236:07AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SABSSAB Biotherapeutics Inc
02/07/20239:04AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
02/03/20234:59PMEdgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SABSSAB Biotherapeutics Inc
02/03/20234:58PMEdgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:SABSSAB Biotherapeutics Inc
01/27/20234:36PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
01/19/20238:00AMGlobeNewswire Inc.SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor ConferenceNASDAQ:SABSSAB Biotherapeutics Inc
01/18/20238:00AMGlobeNewswire Inc.SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD ContractNASDAQ:SABSSAB Biotherapeutics Inc
01/10/20239:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
01/10/20238:00AMGlobeNewswire Inc.SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 DiabetesNASDAQ:SABSSAB Biotherapeutics Inc
01/09/20239:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
01/09/20238:00AMGlobeNewswire Inc.SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech ShowcaseNASDAQ:SABSSAB Biotherapeutics Inc
01/05/20234:24PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
01/05/20238:00AMGlobeNewswire Inc.SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune DiseasesNASDAQ:SABSSAB Biotherapeutics Inc
12/16/20224:35PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SABSSAB Biotherapeutics Inc
12/15/20228:30AMGlobeNewswire Inc.SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San FranciscoNASDAQ:SABSSAB Biotherapeutics Inc
12/12/20229:08AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
12/09/20224:32PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SABSSAB Biotherapeutics Inc
12/09/20229:02AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SABSSAB Biotherapeutics Inc
12/07/20225:16PMGlobeNewswire Inc.SAB Biotherapeutics Announces $7.9 Million Private Placement of Common StockNASDAQ:SABSSAB Biotherapeutics Inc
11/21/20224:47PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SABSSAB Biotherapeutics Inc
11/21/20228:14AMGlobeNewswire Inc.SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 DiabetesNASDAQ:SABSSAB Biotherapeutics Inc
11/18/20229:16AMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SABSSAB Biotherapeutics Inc
11/17/202211:35PMTipRanksRobert W. Baird Keeps Their Buy Rating on SAB Biotherapeutics (SABS)NASDAQ:SABSSAB Biotherapeutics Inc
11/16/20227:45AMTipRanksChardan Capital Remains a Buy on SAB Biotherapeutics (SABS)NASDAQ:SABSSAB Biotherapeutics Inc
11/15/20228:30AMGlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q3 2022 Financial ResultsNASDAQ:SABSSAB Biotherapeutics Inc
11/08/20228:30AMGlobeNewswire Inc.SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022NASDAQ:SABSSAB Biotherapeutics Inc
11/03/20229:00AMGlobeNewswire Inc.SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology ConferenceNASDAQ:SABSSAB Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SABS

Your Recent History

Delayed Upgrade Clock